NCT00259766
Completed
Phase 3
Symbicort and Health Economics in a Real Life Evaluation - SHARE - A Randomised, Open-Label, Parallel-Group, Multicentre Study to Assess the Asthma-Related Health-Care Costs, in Ordinary Clinical Practice During 12 Months
ConditionsAsthma
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- AstraZeneca
- Enrollment
- 1970
- Locations
- 3
- Primary Endpoint
- Asthma-related health-care utilization as measured by total amount of asthma medication purchased and number of contacts with health-care facilities
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent,
- •previously treated with glucocorticosteroids and B2-agonist
Exclusion Criteria
- •History of smoking, pregnancy, any significant disease or disorder which may put the patient at risk because of study participation
Outcomes
Primary Outcomes
Asthma-related health-care utilization as measured by total amount of asthma medication purchased and number of contacts with health-care facilities
Secondary Outcomes
- Number of days patients or assistant persons are absent from work due to patient's asthma
- Number of exacerbations and treatment failures
Study Sites (3)
Loading locations...
Similar Trials
Completed
Not Applicable
Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US StudyAsthmaNCT01287351Research in Real-Life Ltd82,903
Completed
Not Applicable
Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination TherapyAsthmaNCT01697722Research in Real-Life Ltd815,377
Completed
Not Applicable
Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled CorticosteroidsAsthmaNCT01332344GlaxoSmithKline5,180
Completed
Phase 3
Real Life Effectiveness in Asthma of Symbicort Single Inhaler TherapyAsthmaNCT00319306AstraZeneca550
Completed
Not Applicable
Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPDChronic Obstructive Pulmonary DiseaseNCT01141452Research in Real-Life Ltd815,377